The Fatty Liver Index accurately predicted metabolic dysfunction-associated fatty liver disease with an AUROC of 0.776, demonstrating its utility as a simple non-invasive screening tool.
Cross-Sectional (n=852)
No
Does the fatty liver index accurately predict metabolic dysfunction-associated fatty liver disease in adults?
The fatty liver index is a valid and cost-effective non-invasive screening tool for metabolic dysfunction-associated fatty liver disease.
Effect estimate: AUROC 0.776 (95% CI 0.737-0.816)
p-value: p=<0.0001
AIMS: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new nomenclature for nonalcoholic fatty liver. Along with obesity, fatty liver associated with metabolic dysfunction is increasing and has become a serious socioeconomic problem. Non-invasive testing for the confirmation of MAFLD, including the fatty liver index (FLI), can be used as an alternative method for diagnosing steatosis when imaging modalities are not available. To date, few studies have examined the effectiveness and validity of FLI for diagnosing MAFLD. Therefore, this study analyzed the effectiveness and validity of FLI for diagnosing MAFLD. METHODS: Medical records of men and women aged ≥ 19 years who underwent abdominal computed tomography (CT) examination at our facility between March 2012 and October 2019 were retrospectively reviewed. A comparative analysis between non-continuous variables was performed using the chi-squared test. The area under receiver operating characteristic (AUROC) curve was used to verify the effectiveness of FLI as a predictive index for MAFLD. RESULTS: Analysis of the association between MAFLD and abdominal CT revealed that the sensitivity and specificity of FLI for diagnosing MAFLD were 0.712 and 0.713, respectively. The AUROC of FLI for predicting MAFLD was 0.776. CONCLUSIONS: Our study verified the accuracy of FLI for predicting MAFLD using CT. The FLI can be used as a simple and cost-effective tool for screening MAFLD in clinical settings.
A Lum Han (Tue,) conducted a cross-sectional in Metabolic dysfunction-associated fatty liver disease (MAFLD) (n=852). Fatty liver index (FLI) vs. Abdominal computed tomography (CT) was evaluated on Prediction of MAFLD (AUROC 0.776, 95% CI 0.737-0.816, p=<0.0001). The Fatty Liver Index accurately predicted metabolic dysfunction-associated fatty liver disease with an AUROC of 0.776, demonstrating its utility as a simple non-invasive screening tool.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: